AI drug discovery company Insilico Medicine is offering free courses on target

Insilico Medicine, a generative artificial intelligence (AI)-driven drug discovery company, today announced its launch Disease Modeling and Target Identification courses, available free of charge. Through seven lectures, the course guides participants through the latest insights in disease modeling and target discovery – an important area of ​​biomedical research that involves using computational and experimental approaches to gain insight into disease causes and identify potential targets for drug development.

This course uses case studies to illustrate the practical application of the concepts discussed. Specifically, students will have the opportunity to explore a demo version of PandaOmics, Insilico Medicine’s generative AI tool for target discovery, used by many pharmaceutical companies as well as to develop 31 advanced pharmaceutical assets within Insilico’s own pipeline – including two drugs for idiopathic pulmonary fibrosis and COVID -19 is currently in clinical trials.

After completing the course, participants will receive: .

• in-depth knowledge of the challenges and opportunities in drug target discovery, including the emerging role of AI, the achievements, and failures of pharmaceutical companies in recent years and the most promising therapeutic areas;
• practical skills in identifying and evaluating potential drug targets, including familiarity with some popular tools and sources;
• knowledge of the latest trends and emerging topics in target discovery, such as the use of large language models and the evolution of the druggable genome concept;
• exposure to several case studies illustrating the practical application of the concepts discussed, and the ability to critically evaluate and compare various target discovery strategies.

This course is geared toward anyone interested in drug discovery, biomedical research, and healthcare innovation, including researchers, scientists, pharmaceutical professionals, and students pursuing degrees in molecular biology, chemistry, or related fields who want to see how basic science can be applied on the development of new therapies.

“This course is in line with our larger mission to accelerate the discovery and development of new therapeutics by making technological breakthroughs accessible to all scientists, including students, who may be interested in pursuing AI drug discovery,” said Insilico Medicine founder and CEO Alex Zhavoronkov, PhD. , who is one of the course instructors.

Insilico has supported young researchers using its platform before. Three high school researchers used PandaOmics to uncover new targets for glioblastoma and aging, whose results were recently published in the journal Aging. Dan Insilico has been a supporter of the Youth Longevity Association and annually sponsors young scientists to attend the event Conference on Aging Research and Drug Discovery in Copenhagen, a typical event set up by Zhavoronkov.

About Insilico Drugs

Insilico Medicine, an end-to-end clinical-stage artificial intelligence (AI)-based drug discovery company, connects biology, chemistry, and clinical trial analysis using next-generation AI systems. The company has developed an AI platform that uses deep generative models, reinforcement learning, transformers and other modern machine learning techniques to find new targets and design new molecular structures with desired properties. Insilico Medicine provides breakthrough solutions for discovering and developing innovative drugs for cancer, fibrosis, immunity, central nervous system (CNS) and aging-related diseases.

For more information, visit www.insilico.com